| DA.PVG.1AV1-(D4Rat155-D4Rat84) |
maximum body weight loss to initial body weight ratio |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
14 |
5.9 |
% |
3.7 |
13.84 |
body weighing method |
0.0 |
0 |
|
|
69797 |
1162 |
| F344/NHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84476 |
1178 |
| DA/ZtmKini |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
8 |
50.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84515 |
1178 |
| ACI/SegHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84524 |
1178 |
| COP |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
8 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84528 |
1178 |
| LEW.1F |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
50.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84534 |
1178 |
| LEW/Han |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
29 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84513 |
1178 |
| LOU/M |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
5 |
100.0 |
% |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110792 |
3186 |
| LOU/M |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (5 mg) then cyclophosphamide (8 mg) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
100.0 |
% |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110793 |
3186 |
| LEW |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) |
Roth MP, et al., J Immunol 1999 Feb 15;162(4):1917-22. |
central nervous system integrity trait |
not specified |
70 days-122 days |
9 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
|
|
69968 |
1278 |
| DA.PVG.1AV1-(D4Rat155-D4Rat84) |
serum orosomucoid 1 level |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
orosomucoid 1 amount |
both |
120 days-180 days |
14 |
370.0 |
mg/l |
|
|
radial immunodiffusion assay |
0.0 |
0 |
radial immunodiffusion assay |
blood alpha-1-acid glycoprotein amount |
69755 |
1162 |
| DA/Ztm |
post-insult time to onset of experimental arthritis |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
joint integrity trait |
both |
120 days-200 days |
16 |
14.9 |
d |
0.5 |
2.0 |
in vivo visual assessment |
0.0 |
0 |
|
|
69775 |
1162 |
| PVG |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
8 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84531 |
1178 |
| LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
5 |
8.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110800 |
3186 |
| LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
11.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110801 |
3186 |
| LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
8.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110803 |
3186 |
| LOU/M |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
0.0 |
% |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110790 |
3186 |
| LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
3 |
8.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110802 |
3186 |
| LOU/M |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
100.0 |
% |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110795 |
3186 |
| DA/Ztm |
maximum body weight loss to initial body weight ratio |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
16 |
3.2 |
% |
1.8 |
7.2 |
body weighing method |
0.0 |
0 |
|
|
69796 |
1162 |
| COP |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
8 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84514 |
1178 |
| PVG |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
8 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84517 |
1178 |
| LEW.1AR1/Ztm |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
30 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84519 |
1178 |
| BN |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) |
Roth MP, et al., J Immunol 1999 Feb 15;162(4):1917-22. |
central nervous system integrity trait |
not specified |
70 days-122 days |
9 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
|
|
69967 |
1278 |
| DA/Ztm |
serum orosomucoid 1 level |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
orosomucoid 1 amount |
both |
120 days-180 days |
16 |
540.0 |
mg/l |
|
|
radial immunodiffusion assay |
0.0 |
0 |
radial immunodiffusion assay |
blood alpha-1-acid glycoprotein amount |
69753 |
1162 |
| PVG.1AV1 |
percentage of study population developing experimental arthritis during a period of time |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
joint integrity trait |
both |
120 days-200 days |
15 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
|
|
69707 |
1162 |
| LEW.1N |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
6 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84521 |
1178 |
| BN/OlaHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
7 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84523 |
1178 |
| F344/NHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
3 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84526 |
1178 |
| LEW.1WR1/WorBrm |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84532 |
1178 |
| LEW.1N |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
12 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84535 |
1178 |
| LEW.1AV1/Kini |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
6 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84536 |
1178 |
| WF/NHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
5 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84475 |
1178 |
| LOU/M |
post-insult time to onset of experimental autoimmune encephalomyelitis |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
11.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110797 |
3186 |
| LOU/M |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
3 |
100.0 |
% |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110794 |
3186 |
| LEW.1AV1/Kini |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
41 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84522 |
1178 |
| DA/Ztm |
percentage of study population developing experimental arthritis during a period of time |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
joint integrity trait |
both |
120 days-200 days |
16 |
88.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
|
|
69706 |
1162 |
| DA.PVG.1AV1-(D4Rat155-D4Rat84) |
percentage of study population developing experimental arthritis during a period of time |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
joint integrity trait |
both |
120 days-200 days |
14 |
36.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
|
|
69708 |
1162 |
| BN/OlaHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
7 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84473 |
1178 |
| PVG.1AV1 |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
8 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84516 |
1178 |
| LEW.1WR1/WorBrm |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
37 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84518 |
1178 |
| WF/NHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
5 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84525 |
1178 |
| PVG.1AV1 |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
25.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84530 |
1178 |
| LOU/M |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
0.0 |
% |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110791 |
3186 |
| DA.PVG.1AV1-(D4Rat155-D4Rat84) |
post-insult time to onset of experimental arthritis |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
joint integrity trait |
both |
120 days-200 days |
14 |
13.6 |
d |
0.4 |
1.5 |
in vivo visual assessment |
0.0 |
0 |
|
|
69776 |
1162 |
| N:HS |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (50-120 ug) and Freund's complete adjuvant (100 ul) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
central nervous system integrity trait |
both |
132 days-177 days |
217 |
41.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
|
|
66040 |
114 |
| LEW.1F |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84520 |
1178 |
| LEW/Han |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
18 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84527 |
1178 |
| DA/ZtmKini |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
5 |
80.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84529 |
1178 |
| LEW.1AR1/Ztm |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
100.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84533 |
1178 |
| LOU/M |
post-insult time to onset of experimental autoimmune encephalomyelitis |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
5 |
11.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110796 |
3186 |
| LOU/M |
post-insult time to onset of experimental autoimmune encephalomyelitis |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
3 |
11.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110798 |
3186 |
| LOU/M |
post-insult time to onset of experimental autoimmune encephalomyelitis |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
11.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
2592000.0 |
0 |
|
|
110799 |
3186 |
| PVG.1AV1 |
serum orosomucoid 1 level |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
orosomucoid 1 amount |
both |
120 days-180 days |
15 |
340.0 |
mg/l |
|
|
radial immunodiffusion assay |
0.0 |
0 |
radial immunodiffusion assay |
blood alpha-1-acid glycoprotein amount |
69754 |
1162 |
| ACI/SegHsd |
percentage of study population developing experimental autoimmune neuritis during a period of time |
peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) |
de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. |
peripheral nervous system integrity trait |
male |
98 days-200 days |
4 |
0.0 |
% |
|
|
ex vivo visual assessment |
0.0 |
0 |
|
peripheral nervous system integrity trait |
84474 |
1178 |
